Latest Sacral nerve stimulation Stories
MINNETONKA, Minn., Oct. 15, 2012 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today announced that the results of a long-term clinical pilot study using an implantable tibial nerve stimulation device will be presented at the Annual Meeting of the International Continence Society (ICS), October 15-19, 2012 in Beijing, China. Uroplasty acquired rights to the...
MINNEAPOLIS, June 6, 2012 /PRNewswire/ -- - Uroplasty, Inc. (NASDAQ:UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today highlighted results of the STEP Study on percutaneous tibial nerve stimulation (PTNS) treatments for overactive bladder (OAB) using Uroplasty's Urgent® PC Neuromodulation System. The study will be published in a future print edition of Neurourology and Urodynamics...
MINNEAPOLIS, May 24, 2012 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ:UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of patients with voiding dysfunctions, today announced two new research and development initiatives to expand its commitment to using the Company's neuromodulation technology to treat voiding dysfunctions. "We will begin development of an implantable tibial nerve stimulator for the treatment of...
ATLANTA and ROYAL OAK, Mich., May 22, 2012 /PRNewswire/ -- Findings from a multi-center trial led by researchers at Beaumont Hospital in Royal Oak, Mich. may give urologists another minimally invasive treatment option for women with stress urinary incontinence. The study showed that treating a woman with her own muscle-derived stem cells was both safe and effective. Unlike surgical treatments, this procedure takes place in a physician's office. According to the National Institutes...
MINNEAPOLIS, May 21, 2012 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced that the American Urological Association (AUA) issued a clinical guideline titled "Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults," which includes percutaneous tibial nerve stimulation (PTNS) as an integral part of the care path for...
MINNEAPOLIS, May 17, 2012 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ:UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced that at the May 19-22, 2012 Annual Meeting of the American Urological Association (AUA) in Atlanta, GA, there will be two presentations on Uroplasty's Urgent® PC Neuromodulation System. "The presentations on Urgent PC scheduled for the AUA meeting will...
IncoStress, now sold in Canada by Bescot Healthcare Canada, is a device, worn like a tampon, that can help many women who suffer in silence with the potentially devastating disability of Urinary Stress Incontinence. Toronto, Ontario, Canada (PRWEB) March 05, 2012 IncoStress, now available in Canada through Bescot Healthcare, could help end the suffering for the many women who live with Urinary Stress Incontinence - the involuntary loss of urine when, for example, coughing, sneezing,...
MINNEAPOLIS, Feb. 15, 2012 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ:UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today announced the first enrollment of patients in the CONFIDeNT clinical study in the United Kingdom. This large multi-center, placebo-controlled study will enroll over 200 patients in up to 20 centers across the UK. Using Uroplasty's minimally-invasive Urgent® PC Neuromodulation...
MINNEAPOLIS, Nov., 9, 2011 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today announced the issuance of United States Patent No. 8,046,082 covering the stimulator used in the Urgent® PC Neuromodulation System. The Urgent PC Neuromodulation System is an office-based, non-surgical system, used to treat overactive bladder syndrome (OAB) and the associated...
CAMPBELL, Calif., Oct. 14, 2011 /PRNewswire/ -- EMKinetics, Inc. announced today initiation of the TranStim(TM) Transdermal Neuromodulation System pivotal trial for patients suffering from urge incontinence and overactive bladder. The 120-person trial will be conducted at 10-15 US centers. Submission for CE mark and 510(k) clearance will follow the completion of the study. EMKinetics' TranStim therapy builds on the body of evidence that posterior tibial nerve stimulation (PTNS) can...
